194 related articles for article (PubMed ID: 23035208)
1. Homeostatic and tissue reparation defaults in mice carrying selective genetic invalidation of CXCL12/proteoglycan interactions.
Rueda P; Richart A; Récalde A; Gasse P; Vilar J; Guérin C; Lortat-Jacob H; Vieira P; Baleux F; Chretien F; Arenzana-Seisdedos F; Silvestre JS
Circulation; 2012 Oct; 126(15):1882-95. PubMed ID: 23035208
[TBL] [Abstract][Full Text] [Related]
2. Defective angiogenesis in CXCL12 mutant mice impairs skeletal muscle regeneration.
Hardy D; Fefeu M; Besnard A; Briand D; Gasse P; Arenzana-Seisdedos F; Rocheteau P; Chrétien F
Skelet Muscle; 2019 Sep; 9(1):25. PubMed ID: 31533830
[TBL] [Abstract][Full Text] [Related]
3. CXCL12γ isoform is expressed on endothelial and dendritic cells in rheumatoid arthritis synovium and regulates T cell activation.
Santiago B; Izquierdo E; Rueda P; Del Rey MJ; Criado G; Usategui A; Arenzana-Seisdedos F; Pablos JL
Arthritis Rheum; 2012 Feb; 64(2):409-17. PubMed ID: 21953583
[TBL] [Abstract][Full Text] [Related]
4. The CXCL12gamma chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteins.
Rueda P; Balabanian K; Lagane B; Staropoli I; Chow K; Levoye A; Laguri C; Sadir R; Delaunay T; Izquierdo E; Pablos JL; Lendinez E; Caruz A; Franco D; Baleux F; Lortat-Jacob H; Arenzana-Seisdedos F
PLoS One; 2008 Jul; 3(7):e2543. PubMed ID: 18648536
[TBL] [Abstract][Full Text] [Related]
5. The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma.
Ren Z; Lantermans H; Kuil A; Kraan W; Arenzana-Seisdedos F; Kersten MJ; Spaargaren M; Pals ST
J Hematol Oncol; 2021 Jan; 14(1):11. PubMed ID: 33436043
[TBL] [Abstract][Full Text] [Related]
6. The novel CXCL12gamma isoform encodes an unstructured cationic domain which regulates bioactivity and interaction with both glycosaminoglycans and CXCR4.
Laguri C; Sadir R; Rueda P; Baleux F; Gans P; Arenzana-Seisdedos F; Lortat-Jacob H
PLoS One; 2007 Oct; 2(10):e1110. PubMed ID: 17971873
[TBL] [Abstract][Full Text] [Related]
7. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization.
Rusnati M; Presta M
Int J Clin Lab Res; 1996; 26(1):15-23. PubMed ID: 8739851
[TBL] [Abstract][Full Text] [Related]
8. Developmental expression profile of the CXCL12gamma isoform: insights into its tissue-specific role.
Franco D; Rueda P; Lendínez E; Arenzana-Seisdedos F; Caruz A
Anat Rec (Hoboken); 2009 Jun; 292(6):891-901. PubMed ID: 19462459
[TBL] [Abstract][Full Text] [Related]
9. Role of TPBG (Trophoblast Glycoprotein) Antigen in Human Pericyte Migratory and Angiogenic Activity.
Spencer HL; Jover E; Cathery W; Avolio E; Rodriguez-Arabaolaza I; Thomas AC; Alvino VV; Sala-Newby G; Dang Z; Fagnano M; Reni C; Rowlinson J; Vono R; Spinetti G; Beltrami AP; Gargioli C; Caporali A; Angelini G; Madeddu P
Arterioscler Thromb Vasc Biol; 2019 Jun; 39(6):1113-1124. PubMed ID: 31018661
[TBL] [Abstract][Full Text] [Related]
10. Heparan sulfate differentially controls CXCL12α- and CXCL12γ-mediated cell migration through differential presentation to their receptor CXCR4.
Connell BJ; Sadir R; Baleux F; Laguri C; Kleman JP; Luo L; Arenzana-Seisdedos F; Lortat-Jacob H
Sci Signal; 2016 Nov; 9(452):ra107. PubMed ID: 27803285
[TBL] [Abstract][Full Text] [Related]
11. Syndecan-4 is a signaling molecule for stromal cell-derived factor-1 (SDF-1)/ CXCL12.
Charnaux N; Brule S; Hamon M; Chaigneau T; Saffar L; Prost C; Lievre N; Gattegno L
FEBS J; 2005 Apr; 272(8):1937-51. PubMed ID: 15819887
[TBL] [Abstract][Full Text] [Related]
12. CXCL12 is displayed by rheumatoid endothelial cells through its basic amino-terminal motif on heparan sulfate proteoglycans.
Santiago B; Baleux F; Palao G; Gutiérrez-Cañas I; Ramírez JC; Arenzana-Seisdedos F; Pablos JL
Arthritis Res Ther; 2006; 8(2):R43. PubMed ID: 16507142
[TBL] [Abstract][Full Text] [Related]
13. The potent anti-HIV activity of CXCL12gamma correlates with efficient CXCR4 binding and internalization.
Altenburg JD; Jin Q; Alkhatib B; Alkhatib G
J Virol; 2010 Mar; 84(5):2563-72. PubMed ID: 20015992
[TBL] [Abstract][Full Text] [Related]
14. Shock wave treatment induces angiogenesis and mobilizes endogenous CD31/CD34-positive endothelial cells in a hindlimb ischemia model: implications for angiogenesis and vasculogenesis.
Tepeköylü C; Wang FS; Kozaryn R; Albrecht-Schgoer K; Theurl M; Schaden W; Ke HJ; Yang Y; Kirchmair R; Grimm M; Wang CJ; Holfeld J
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):971-8. PubMed ID: 23395097
[TBL] [Abstract][Full Text] [Related]
15. Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton.
Cazes A; Galaup A; Chomel C; Bignon M; Bréchot N; Le Jan S; Weber H; Corvol P; Muller L; Germain S; Monnot C
Circ Res; 2006 Nov; 99(11):1207-15. PubMed ID: 17068295
[TBL] [Abstract][Full Text] [Related]
16. The core protein of the matrix-associated heparan sulfate proteoglycan binds to fibronectin.
Heremans A; De Cock B; Cassiman JJ; Van den Berghe H; David G
J Biol Chem; 1990 May; 265(15):8716-24. PubMed ID: 2140362
[TBL] [Abstract][Full Text] [Related]
17. Perlecan heparan sulfate proteoglycan is a critical determinant of angiogenesis in response to mouse hind-limb ischemia.
Qiang B; Lim SY; Lekas M; Kuliszewski MA; Wolff R; Osherov AB; Rudenko D; Leong-Poi H; Noyan H; Husain M; Tran K; Tryggvason K; Hedin U; Tran-Lundmark K; Strauss BH
Can J Cardiol; 2014 Nov; 30(11):1444-51. PubMed ID: 25249499
[TBL] [Abstract][Full Text] [Related]
18. Combination of stromal-derived factor-1alpha and vascular endothelial growth factor gene-modified endothelial progenitor cells is more effective for ischemic neovascularization.
Yu JX; Huang XF; Lv WM; Ye CS; Peng XZ; Zhang H; Xiao LB; Wang SM
J Vasc Surg; 2009 Sep; 50(3):608-16. PubMed ID: 19595531
[TBL] [Abstract][Full Text] [Related]
19. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization.
Yamaguchi J; Kusano KF; Masuo O; Kawamoto A; Silver M; Murasawa S; Bosch-Marce M; Masuda H; Losordo DW; Isner JM; Asahara T
Circulation; 2003 Mar; 107(9):1322-8. PubMed ID: 12628955
[TBL] [Abstract][Full Text] [Related]
20. Deletion of FHL2 gene impaired ischemia-induced blood flow recovery by modulating circulating proangiogenic cells.
Huang PH; Chen CY; Lin CP; Wang CH; Tsai HY; Lo WY; Leu HB; Chen JW; Lin SJ; Chu PH
Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):709-17. PubMed ID: 23413425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
